Corcept Therapeutics (CH:HTD)
NASDAQ:HTD
HTD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a sizable cash position provide durable financial runway to fund commercial launches and R&D. The equity cushion (~$638M–$680M historically) reduces refinancing risk, supports strategic flexibility during a temporary profitability swing, and underpins multi-year growth investments.
Lifyorli Approval With Strong Survival DataRegulatory approval and a 35% mortality reduction establish Lifyorli as a clinically meaningful oncology therapy. Publication in The Lancet and guideline inclusion signal durable clinical adoption potential, creating a high-margin, potentially large oncology revenue stream that diversifies the company long-term.
Expanding Addressable Market And Raised GuidanceManagement raised guidance backed by record endocrinology demand and trials (CATALYST, MOMENTUM) that increase screening and diagnosis. These durable drivers underpin management's multi-year targets (Cushing's ~$2B; Lifyorli >$1B), supporting sustainable revenue growth beyond near-term noise.
Bears Say
Profitability CompressionDespite very high gross margins (~98%), operating expenses for launches and investment caused meaningful margin erosion and a Q1 net loss. If operating leverage does not recover as volumes scale, sustained margin pressure could erode cash flow and force tougher capital allocation choices over the next several quarters.
Revenue Concentration On KorlymHistorically, Corcept's commercial profile has been heavily reliant on a single approved product. Until Lifyorli and other programs scale, concentration risk makes revenues vulnerable to reimbursement, prescribing patterns, or competitive/intake changes, delaying durable diversification benefits.
Regulatory Review Uncertainty For RelacorilantA resubmission that requires additional analyses signals unresolved FDA questions and creates timing risk. Even with supportive pivotal data, the six-month review and any potential label or post‑market requirements introduce regulatory uncertainty that can materially affect near- to medium-term commercialization plans.
Corcept Therapeutics News
HTD FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is CHF7.38B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 40 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.234 earnings per share for the quarter, missing the consensus estimate of -$0.086 by -$0.148.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is <0.01.
How many shares outstanding does Corcept Therapeutics have?
Currently, no data Available
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of -$0.234 in its last earnings report, missing expectations of -$0.086. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CH:HTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF79.13 (― Downside)
CHF79.13 (― Downside)
Insider Transactions
Sold Shares
Worth CHF1.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.54%
12-Months-Change
Fundamentals
Return on Equity
7.50%
Trailing 12-Months
Asset Growth
-3.73%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
HTD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by major clinical and regulatory milestones (Lifyorli FDA approval with a significant survival benefit, landmark CATALYST and MOMENTUM findings that broaden the addressable market, robust patient and prescriber growth, raised 2026 guidance, and compelling ALS and MASH data). Near-term negatives include a Q1 earnings swing to a net loss, temporary revenue headwinds from insurance reauthorizations and a pharmacy-transition backlog, and tolerability-related discontinuations in DAZALS that require mitigation. On balance, the company demonstrated durable commercial traction, an expanding pipeline with high-impact results, and clear plans to address operational issues, leading to a favorable outlook.View all CH:HTD earnings summariesHTD Stock 12 Month Forecast
Average Price Target
$79.13
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Options Prices
Currently, No data available
---